디지털 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Digital Therapeutics Market size is expected to reach USD 99.67 Billion in 2034 from USD 10.60 Billion (2025) growing at a CAGR of 28.28% during 2026-2034.

The global digital therapeutics market has grown rapidly as healthcare providers adopt technology-driven treatment solutions. Digital therapeutics use software-based programs to treat, manage, or prevent medical conditions through evidence-based interventions. These solutions are commonly delivered through mobile applications, wearable devices, and online platforms.

Several drivers are supporting the growth of the digital therapeutics market. Increasing prevalence of chronic diseases and growing adoption of digital health technologies have encouraged the development of software-based treatment tools. Healthcare providers are also exploring digital therapeutics as cost-effective solutions that improve patient engagement and treatment adherence.

Looking ahead, the digital therapeutics market is expected to expand as healthcare systems embrace digital transformation. Advances in artificial intelligence, data analytics, and remote monitoring technologies may enhance treatment effectiveness. As patients and providers increasingly adopt digital health tools, digital therapeutics will likely become an important component of modern healthcare.

MARKET SEGMENTATION

By Application

• Diabetes
• Obesity
• CVD
• Respiratory Diseases
• Smoking Cessation
• CNS Diseases
• Others

By End Use

• Patients
• Providers
• Payers
• Employers
• Others

COMPANIES PROFILED

• Omada Health Inc, Welldoc Inc, 2Morrow Inc, Livongo Health Inc Teladoc Health Inc, Propeller Health ResMed, Fitbit LLC, Mango Health, Canary Health, Noom Inc, Pear Therapeutics Inc, Akili Interactive Labs Inc, Hygieia, DarioHealth Corp, BigHealth, GAIA AG, Limbix Health Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL DIGITAL THERAPEUTICS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Obesity Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. CVD Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Respiratory Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Smoking Cessation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. CNS Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DIGITAL THERAPEUTICS MARKET: BY END USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End Use
• 5.2. Patients Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Providers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Payers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Employers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DIGITAL THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Application
  • 6.2.2 By End Use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Application
  • 6.3.2 By End Use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Application
  • 6.4.2 By End Use
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Application
  • 6.5.2 By End Use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Application
  • 6.6.2 By End Use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL DIGITAL THERAPEUTICS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Omada Health Inc
  • 8.2.2 Welldoc Inc
  • 8.2.3 2Morrow Inc
  • 8.2.4 Livongo Health Inc. (Teladoc Health Inc.)
  • 8.2.5 Propeller Health (ResMed)
  • 8.2.6 Fitbit LLC
  • 8.2.7 Mango Health
  • 8.2.8 Canary Health
  • 8.2.9 Noom Inc
  • 8.2.10 Pear Therapeutics Inc
  • 8.2.11 Akili Interactive Labs Inc
  • 8.2.12 Hygieia
  • 8.2.13 DarioHealth Corp
  • 8.2.14 BigHealth
  • 8.2.15 GAIA AG
  • 8.2.16 Limbix Health Inc